These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35288545)

  • 1. Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial.
    Tiwari AK; Zai CC; Altar CA; Tanner JA; Davies PE; Traxler P; Li J; Cogan ES; Kucera MT; Gugila A; Braganza N; Emmerson H; Zai G; Müller DJ; Levitan R; Kloiber S; Daskalakis ZJ; Frey BN; Bowen JM; Tarride JE; Tytus R; Chandrasena R; Voudouris N; Taylor VH; Tempier R; Sharma V; Vasudev A; Dzongowski P; Pliamm L; Greenspoon T; Dechairo BM; Kennedy JL
    Transl Psychiatry; 2022 Mar; 12(1):101. PubMed ID: 35288545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial.
    Dunlop BW; Parikh SV; Rothschild AJ; Thase ME; DeBattista C; Conway CR; Forester BP; Mondimore FM; Shelton RC; Macaluso M; Logan J; Traxler P; Li J; Johnson H; Greden JF
    BMC Psychiatry; 2019 Dec; 19(1):420. PubMed ID: 31881956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.
    Greden JF; Parikh SV; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Mondimore FM; Shelton RC; Macaluso M; Li J; Brown K; Gilbert A; Burns L; Jablonski MR; Dechairo B
    J Psychiatr Res; 2019 Apr; 111():59-67. PubMed ID: 30677646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression.
    Forester BP; Parikh SV; Weisenbach S; Ajilore O; Vahia I; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Shelton RC; Macaluso M; Li J; Traxler P; Logan J; Brown L; Dechairo B; Greden JF
    Am J Geriatr Psychiatry; 2020 Sep; 28(9):933-945. PubMed ID: 32513518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.
    Thase ME; Parikh SV; Rothschild AJ; Dunlop BW; DeBattista C; Conway CR; Forester BP; Mondimore FM; Shelton RC; Macaluso M; Li J; Brown K; Jablonski MR; Greden JF
    J Clin Psychiatry; 2019 Oct; 80(6):. PubMed ID: 31721487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.
    Oslin DW; Lynch KG; Shih MC; Ingram EP; Wray LO; Chapman SR; Kranzler HR; Gelernter J; Pyne JM; Stone A; DuVall SL; Lehmann LS; Thase ME; ; Aslam M; Batki SL; Bjork JM; Blow FC; Brenner LA; Chen P; Desai S; Dieperink EW; Fears SC; Fuller MA; Goodman CS; Graham DP; Haas GL; Hamner MB; Helstrom AW; Hurley RA; Icardi MS; Jurjus GJ; Kilbourne AM; Kreyenbuhl J; Lache DJ; Lieske SP; Lynch JA; Meyer LJ; Montalvo C; Muralidhar S; Ostacher MJ; Paschall GY; Pfeiffer PN; Prieto S; Przygodzki RM; Ranganathan M; Rodriguez-Suarez MM; Roggenkamp H; Schichman SA; Schneeweis JS; Simonetti JA; Steinhauer SR; Suppes T; Umbert MA; Vassy JL; Voora D; Wiechers IR; Wood AE
    JAMA; 2022 Jul; 328(2):151-161. PubMed ID: 35819423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis.
    Brown L; Vranjkovic O; Li J; Yu K; Al Habbab T; Johnson H; Brown K; Jablonski MR; Dechairo B
    Pharmacogenomics; 2020 Jun; 21(8):559-569. PubMed ID: 32301649
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression.
    Rothschild AJ; Parikh SV; Hain D; Law R; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Shelton RC; Macaluso M; Brown K; Lewis D; Gutin A; Jablonski MR; Greden JF
    Psychiatry Res; 2021 Feb; 296():113649. PubMed ID: 33360967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder.
    Perlis RH; Dowd D; Fava M; Lencz T; Krause DS
    Depress Anxiety; 2020 Sep; 37(9):834-841. PubMed ID: 32383277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
    Pérez V; Salavert A; Espadaler J; Tuson M; Saiz-Ruiz J; Sáez-Navarro C; Bobes J; Baca-García E; Vieta E; Olivares JM; Rodriguez-Jimenez R; Villagrán JM; Gascón J; Cañete-Crespillo J; Solé M; Saiz PA; Ibáñez Á; de Diego-Adeliño J; ; Menchón JM
    BMC Psychiatry; 2017 Jul; 17(1):250. PubMed ID: 28705252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis.
    Rosenblat JD; Lee Y; McIntyre RS
    J Affect Disord; 2018 Dec; 241():484-491. PubMed ID: 30149336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.
    Winner JG; Carhart JM; Altar CA; Allen JD; Dechairo BM
    Discov Med; 2013 Nov; 16(89):219-27. PubMed ID: 24229738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.
    Rosenblat JD; Lee Y; McIntyre RS
    J Clin Psychiatry; 2017 Jun; 78(6):720-729. PubMed ID: 28068459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.
    Bousman CA; Arandjelovic K; Mancuso SG; Eyre HA; Dunlop BW
    Pharmacogenomics; 2019 Jan; 20(1):37-47. PubMed ID: 30520364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility.
    Bradley P; Shiekh M; Mehra V; Vrbicky K; Layle S; Olson MC; Maciel A; Cullors A; Garces JA; Lukowiak AA
    J Psychiatr Res; 2018 Jan; 96():100-107. PubMed ID: 28992526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression.
    Vande Voort JL; Orth SS; Shekunov J; Romanowicz M; Geske JR; Ward JA; Leibman NI; Frye MA; Croarkin PE
    J Am Acad Child Adolesc Psychiatry; 2022 Jan; 61(1):46-55. PubMed ID: 34099307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial).
    Minelli A; Barlati S; Vitali E; Bignotti S; Dattilo V; Tura GB; Maffioletti E; Giacopuzzi E; Santoro V; Perusi G; Cobelli C; Magri C; Bonizzato S; Bocchio-Chiavetto L; Spina E; Vita A; Gennarelli M
    Trials; 2021 Dec; 22(1):896. PubMed ID: 34895291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.